NCT06739252 2026-01-28
Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA
Peking University
Phase 2 Terminated
Clinical Trials
9 trialsNCT06505486 2024-07-17
GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Recruiting
NCT06320301 2024-03-20
Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT01726582 2023-08-14
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Medical College of Wisconsin
Phase 2 Completed
NCT05036798 2022-09-07
Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05517239 2022-08-26
PEACH
Yonsei University
Phase 2 Completed
NCT01267344 2016-05-04
BTC
National Health Research Institutes, Taiwan
Phase 2 Completed
NCT00169195 2015-09-02
Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma
Lymphoma Study Association
Phase 2 Completed
NCT00127595 2005-08-24
Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated